Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

FDA Issues Alert Regarding Efficacy and Safety of Atezolizumab/Paclitaxel in Breast Cancer

September 8th 2020

The FDA has issued an alert that the phase 3 IMpassion131 trial failed to show the effectiveness of atezolizumab plus paclitaxel in treatment-naïve patients with inoperable locally advanced or metastatic triple-negative breast cancer.

Breast Cancer–Specific Survival Worse Among Survivors of Childhood or Young Adult Primary Cancer Treated With Radiotherapy

September 8th 2020

Premenopausal women with breast cancer who were previously treated with radiotherapy for a primary childhood, adolescent, or young adult cancer were found to have worse breast cancer–specific survival.

New Era for Targeting HER2 Beckons in Breast Cancer and Beyond

September 3rd 2020

Precision medicine advancements are opening a new chapter in the development of anticancer therapies that target the HER2 pathway, resulting in 3 approvals for breast cancer in less than a year and raising hopes for attacking other cancer types.

Dr. Ahmed on the Impact of Neratinib on CNS Metastases in HER2+ Breast Cancer

September 3rd 2020

Kamran A. Ahmed, MD, discusses the impact of neratinib on patients with central nervous system metastases and HER2-positive breast cancer.

Adjuvant Endocrine Therapy Boosts Survival in Small, HR+, ERBB2- Breast Cancer

September 3rd 2020

Adjuvant endocrine therapy was found to be associated with improved overall survival in patients with hormone receptor–positive, ERBB2-negative, node-negative breast cancer with small but invasive tumors.

Dr. Soliman the Utility of ADCs in Breast Cancer

September 1st 2020

Hatem Soliman, MD, discusses the utility of antibody-drug conjugates in breast cancer.

FDA Grants Priority Review to Oral Paclitaxel/Encequidar for Metastatic Breast Cancer

September 1st 2020

The FDA has granted a priority review to a new drug application for oral paclitaxel and encequidar for use in patients with metastatic breast cancer.

Dr. Greenlee on Mitigating the Risk of Cardiovascular Disease in Breast Cancer

August 31st 2020

Heather Greenlee, ND, PhD, MPH, provides strategies to mitigate the increased risk of cardiovascular disease in women with breast cancer.

Dr. O’Regan on the Utility of CDK4/6 Inhibitors in Breast Cancer

August 31st 2020

Ruth O’Regan, MD, discusses the utility of CDK4/6 inhibitors in breast cancer.

Dr. Hamilton on Recent Advances in HER2+ Breast Cancer

August 31st 2020

Erika P. Hamilton, MD, discusses the roles of fam-trastuzumab deruxtecan-nxki and tucatinib in HER2-positive breast cancer.

Dr. Sharma on the Rationale to Combine Veliparib With Chemotherapy in TNBC

August 31st 2020

Priyanka Sharma, MD, discusses the rationale to combine veliparib with chemotherapy in triple-negative breast cancer.

Therapeutic Considerations in Metastatic HER2+ Breast Cancer

August 29th 2020

Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Sara Tolaney, MD, MPH, and Komal Jhaveri, MD, FACP, on Wednesday, October 7, 2020 at 8 PM EDT.

Novel Approaches to Metastatic HER2+ Breast Cancer

August 29th 2020

Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Debu Tripathy, MD and Michelina Cairo, MD, on Tuesday, October 13, 2020 at 8:00 PM CDT.

CDK4/6 Inhibitors Shift Standards in HR+ Metastatic Breast Cancer

August 28th 2020

Denise A. Yardley, MD, highlights the evolving role of adjuvant CDK4/6 inhibition in HR-positive metastatic breast cancer.

Considerations in Metastatic HER2+ Breast Cancer

August 28th 2020

Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Mark Daniel Pegram, MD and Julie R. Gralow, MD, on Thursday, October 15, 2020 at 8:00 PM PDT.

Dr. Pegram on the DESTINY-Breast01 Trial With Trastuzumab Deruxtecan in HER2+ Breast Cancer

August 27th 2020

Mark D. Pegram, MD, discusses the results of the phase 2 DESTINY-Breast01 study examining fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.

Dr. Brufsky on Treatment Approaches for Early-Stage HER2+ Breast Cancer

August 27th 2020

Adam M. Brufsky, MD, PhD, discusses the treatment of early-stage, HER2-positive breast cancer.

Trastuzumab Deruxtecan, Tucatinib Generate Excitement in Metastatic HER2+ Breast Cancer

August 27th 2020

Erika P. Hamilton, MD, discusses the pivotal data that led to the approvals of trastuzumab deruxtecan and tucatinib in metastatic HER2-positive breast cancer, factors considered in terms of treatment selection, and emerging agents under exploration.

Dr. Gradishar on the Benefit of Trastuzumab Deruxtecan in HER2+ Breast Cancer

August 27th 2020

William J. Gradishar, MD, discusses the benefit of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer and stable brain metastases.

Dr. Partridge on the Role of Genomic Testing in Breast Cancer

August 25th 2020

Ann H. Partridge, MD, MPH, discusses the role of genomic testing in breast cancer.